CymitQuimica logo

CAS 143443-90-7

:

Ifetroban

Description:
Ifetroban is a synthetic compound primarily recognized for its role as a selective thromboxane A2 receptor antagonist. It is characterized by its ability to inhibit platelet aggregation and vasoconstriction, making it of interest in cardiovascular research and potential therapeutic applications. The molecular structure of Ifetroban features a unique arrangement of functional groups that contribute to its biological activity. It is typically administered in a pharmaceutical context, and its pharmacokinetics involve absorption, distribution, metabolism, and excretion processes that are crucial for its efficacy and safety profile. Ifetroban has been studied for its potential benefits in conditions such as hypertension and other cardiovascular diseases, although its clinical use may vary based on regulatory approvals and ongoing research. As with many pharmacological agents, understanding its mechanism of action, side effects, and interactions with other drugs is essential for its application in medical settings.
Formula:C25H32N2O5
InChI:InChI=1S/C25H32N2O5/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29)/t18-,20-,21+,23-/m0/s1
InChI key:InChIKey=BBPRUNPUJIUXSE-DXKRWKNPSA-N
SMILES:C([C@@H]1[C@@H]([C@@]2(O[C@]1(CC2)[H])[H])C3=NC(C(NCCCCC)=O)=CO3)C4=C(CCC(O)=O)C=CC=C4
Synonyms:
  • 2-[[(1S,2R,3S,4R)-3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid
  • Benzenepropanoic acid, 2-[[(1S,2R,3S,4R)-3-[4-[(pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-
  • 7-Oxabicyclo[2.2.1]heptane, benzenepropanoic acid deriv.
  • Benzenepropanoic acid, 2-[[3-[4-[(pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-, [1S-(exo,exo)]-
  • BMS 180291
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 1 products.